Скачать с ютуб Remaining questions surrounding HER2-low breast cancer – how low can you go? в хорошем качестве

Remaining questions surrounding HER2-low breast cancer – how low can you go?

Paolo Tarantino, MD, Dana-Farber Cancer Institute, Boston, MA, discusses key remaining questions surrounding HER2-low breast cancer, including whether the benefit of trastuzumab deruxtecan (T-DXd) to HER2-0 and whether HER2 can be better quantified in breast cancer. The Phase II DAISY (NCT04132960) trial demonstrated a 30% objective response rate with T-DXd in patients with HER2-0 metastatic breast cancer suggesting targetability for HER2-0 breast cancers. Additionally, through quantitative measurements HER2-0 breast cancers have been shown to harbour HER2 expression that cannot be detected by immunohistochemistry (IHC), suggesting quantitative measurements of HER2 expression could expand the detectability of HER2. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.